Sign in
Taking people in United StatesNo phase

Biomarkers in the Retina for Prognosticating Mental Health Treatments

Key facts

Who runs it
VA Puget Sound Health Care System
Where
Seattle, United StatesSee the site
Trial code
Status
Recruiting
People taking part
50 people, planned
Started
12 Feb 2024
Expected to end
1 Sept 2030
Type of study
Interventional
Treatments tested
  • RETeval
Record updated
12 April 2024

Who can take part

Age
21 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Veteran of the U.S. Armed Forces
  • Current diagnosis of PTSD

Who cannot take part

  • Previous ERG deficits
  • Allergy or previous adverse reaction to sertraline or SSRI
  • Any use in the time period of at least 6 half-lives prior to baseline of sertraline or other drugs acting on serotonin and/or unwillingness to avoid these medications for the duration of the study
  • Known diagnosis of a primary psychotic or major neurocognitive disorder
  • History of acute angle closure glaucoma
  • Known inherited retinal disease
  • Known photosensitive epilepsy
  • Allergy to Sensor Strip gel
  • Hepatic failure
  • Significant bilateral visual loss
  • Known current pregnancy or lactation
  • Damage to orbit structure or open lesion in soft tissue surrounding the eye

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 75 years old?

Where in United States

  • VA Puget Sound Health Care SystemSeattle, United StatesContact: Rebecca C Hendrickson, MD, PhDTaking people

About the trial

What the trial wants to find out

Title: ERG as a potential biomarker of SSRI-responsive PTSD: A pilot study

Read full original descriptionShow less

Posttraumatic stress disorder (PTSD) affects many individuals who experience a traumatic event. Previous studies suggest that there is a connection between the brain and the retina, and that the electroretinogram (ERG) may be a valuable biomarker to tell us more about signals in the brain that are related to mental health disorders like PTSD. The goal of this observational study is to examine the ERG waveform in veterans with PTSD before and after a single dose of the selective serotonin reuptake inhibitor (SSRI), sertraline. Sertraline is one of two FDA-approved medications for the treatment of PTSD. The main questions this pilot study aims to answer are:

1. How does sertraline, an SSRI, influence the ERG waveform in veterans with PTSD? 2. Is there a significant correlation between baseline ERG signals and the change in ERG following SSRI treatment?

Participants will be asked to:

* Undergo ERG recordings before and after a single dose of sertraline. * Provide relevant clinical information related to PTSD symptoms and treatment history.

Following the initial study visits, participants will enter an optional open label phase of the study in which qualifying participants who initiate antidepressant treatment through routine clinical care will be invited back for a follow-up ERG recording.

The group in the trial

  • ERG, all participantsTreatment being tested

    All participants undergo ERG recording before and after a single dose of sertraline 50 mg.

    Treatment: RETeval

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Electroretinogram (ERG) as a Potential Biomarker of Serotonin Selective Reuptake Inhibitor (SSRI)-Responsive Posttraumatic Stress Disorder (PTSD): A Pilot Study
Criteria questions
Built from NCT06363968, who can take part
Record updated
12 April 2024